Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) Market Outlook 2025-2034: Market Share, and Growth Analysis

The Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) Market is valued at USD 8 billion in 2025 and is projected to grow at a CAGR of 24.4% to reach USD 57 billion by 2034.

The cell and gene therapy CDMO market is a specialized and rapidly growing sector within the biopharmaceutical industry. CDMOs provide critical end-to-end services that support the development and manufacturing of cell and gene therapies, which are among the most advanced and promising treatments for complex diseases. These organizations offer expertise in process development, analytical testing, regulatory compliance, and large-scale production, helping biotechs and pharmaceutical companies bring innovative therapies to market more efficiently and cost-effectively.

The unique requirements of cell and gene therapies, including their highly personalized nature, complex manufacturing processes, and stringent quality standards, drive the demand for specialized CDMO services. As the number of clinical trials and commercial approvals in the cell and gene therapy space continues to grow, CDMOs are playing a pivotal role in overcoming production challenges, ensuring regulatory compliance, and accelerating time-to-market.

Geographically, North America and Europe dominate the cell and gene therapy CDMO market due to well-established biopharma industries, significant R&D investment, and supportive regulatory environments. Meanwhile, the Asia-Pacific region is emerging as a key growth area, driven by increasing healthcare investment, a growing talent pool, and efforts to establish local manufacturing capabilities. This global expansion reflects the rising demand for contract development and manufacturing services as the cell and gene therapy pipeline matures.

Key Insights: Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) Market

• Increased adoption of advanced bioprocessing technologies, including single-use systems and closed production platforms, to streamline manufacturing.
• Growing demand for flexible and modular facilities that can adapt to various production scales and therapy types.
• Rising integration of digital tools and automation, enabling real-time monitoring, predictive maintenance, and enhanced product consistency.
• Expanding partnerships between CDMOs and biopharma companies to accelerate clinical development and commercialization.
• Focus on sustainability and eco-friendly manufacturing practices, including reducing waste and improving energy efficiency.
• Rapid growth in the number of cell and gene therapy candidates entering clinical trials, creating a pressing need for scalable manufacturing solutions.
• Increasing regulatory approvals for cell and gene therapies, boosting demand for CDMO services to meet commercial production requirements.
• Advancements in gene editing and cell engineering technologies, driving more complex manufacturing needs that CDMOs are equipped to handle.
• Cost advantages and risk reduction for biotechs and smaller pharmaceutical companies by outsourcing to experienced CDMOs.
• High capital investment requirements for building and maintaining state-of-the-art manufacturing facilities.
• Limited availability of skilled workforce trained in cell and gene therapy manufacturing and quality control.
• Navigating stringent and evolving regulatory requirements across multiple regions.

Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) Market Segmentation

By Product Type

• Gene Therapy
• Gene-Modified Cell Therapy
• Cell Therapy

By Phase

• Phase 1
• Phase 2
• Phase 3
• Phase 4

By Indication

• Oncology
• Infectious Diseases
• Neurological Disorders
• Rare Diseases
• Other Indications

Key Companies Analysed

• Pfizer Inc
• Merck & Co. Inc.
• Thermo Fisher Scientific Inc
• Novartis AG
• FUJIFILM Diosynth Biotechnologies
• AGC Biologics
• Ajinomoto Co Inc
• Lonza Group
• Catalent Inc
• Charles River Laboratories International Inc
• Sartorius Stedim Biotech
• Samsung Biologics Co Ltd
• WuXi Biologics
• Recipharm AB
• Almac Group Ltd
• KBI Biopharma
• Rentschler Biopharma
• Bio Elpida
• Oxford BioMedica Plc
• Avid Bioservices Inc
• Cell and Gene Therapy Catapult
• VGXI Inc
• Genezen Laboratories Inc.
• Pluri Inc.
• OmniaBio Inc.

Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) Market Analytics

The report employs rigorous tools, including Porter’s Five Forces, value chain mapping, and scenario-based modeling, to assess supply-demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends.

Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behavior are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.

Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) Market Competitive Intelligence

The competitive landscape is mapped through proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analyzed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption.

Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across energy and industrial corridors.

Countries Covered

• North America - Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) market data and outlook to 2034
  • United States
  • Canada
  • Mexico
  
  
• Europe - Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) market data and outlook to 2034
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • BeNeLux
  • Russia
  • Sweden
  
  
• Asia-Pacific - Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) market data and outlook to 2034
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Malaysia
  • Vietnam
  
  
• Middle East and Africa - Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) market data and outlook to 2034
  • Saudi Arabia
  • South Africa
  • Iran
  • UAE
  • Egypt
  
  
• South and Central America - Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) market data and outlook to 2034
  • Brazil
  • Argentina
  • Chile
  • Peru

Research Methodology

This study combines primary inputs from industry experts across the Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.

Key Questions Addressed

• What is the current and forecast market size of the Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) industry at global, regional, and country levels?
• Which types, applications, and technologies present the highest growth potential?
• How are supply chains adapting to geopolitical and economic shocks?
• What role do policy frameworks, trade flows, and sustainability targets play in shaping demand?
• Who are the leading players, and how are their strategies evolving in the face of global uncertainty?
• Which regional “hotspots” and customer segments will outpace the market, and what go-to-market and partnership models best support entry and expansion?
• Where are the most investable opportunities - across technology roadmaps, sustainability-linked innovation, and M&A - and what is the best segment to invest over the next 3-5 years?

Your Key Takeaways from the Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) Market Report

• Global Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) market size and growth projections (CAGR), 2024-2034
• Impact of Russia-Ukraine, Israel-Palestine, and Hamas conflicts on Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) trade, costs, and supply chains
• Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) market size, share, and outlook across 5 regions and 27 countries, 2023-2034
• Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) market size, CAGR, and market share of key products, applications, and end-user verticals, 2023-2034
• Short- and long-term Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) market trends, drivers, restraints, and opportunities
• Porter’s Five Forces analysis, technological developments, and Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) supply chain analysis
• Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) trade analysis, Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) market price analysis, and Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) supply/demand dynamics
• Profiles of 5 leading companies - overview, key strategies, financials, and products
• Latest Cell and Gene Therapy Contract Development and Manufacturing Organization (Cdmo) market news and developments

Additional Support

With the purchase of this report, you will receive:

• An updated PDF report and an MS Excel data workbook containing all market tables and figures for easy analysis.
• 7-day post-sale analyst support for clarifications and in-scope supplementary data, ensuring the deliverable aligns precisely with your requirements.
• Complimentary report update to incorporate the latest available data and the impact of recent market developments.

This product will be delivered within 1-3 business days.